Latest Neurodegeneration Stories
People diagnosed with Huntington's disease, most in their mid-thirties and forties, face a devastating prognosis: complete mental, physical, and behavioral decline within two decades.
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
--Research Published in the Journal of Molecular Biology-- CAMBRIDGE, Mass., April 22, 2014 /PRNewswire/ -- Researchers from NeuroPhage
Scientist's 'monumental' discoveries underlie one of the largest fields in modern biomedical research, including efforts to treat cancer and neurodegenerative diseases ALBANY, N.Y.,
Alzheimer's disease, the primary cause of dementia in the elderly, imposes a tremendous social and economic burden on modern society.
Biomedical research institute appoints two key positions, expanding its impact on neurodegenerative science GRAND RAPIDS, Mich., March 26, 2014 /PRNewswire/ --
--Funds Will Advance Novel Approach for Treatment of Alzheimer's Disease and Other Diseases of Protein Aggregation-- CAMBRIDGE, Mass., March 25, 2014 /PRNewswire/ -- NeuroPhage Pharmaceuticals,
The MSA Coalition announced in January 2014 the funding of five MSA research grants for a total of $219,000 including the project "Peripheral delivery of brain-targeted neurosin as a novel
The MSA Coalition announced in January 2014 the funding of five MSA research grants for a total of $219,000 including the project "Stem cell-based Therapeutics Platform for MSA." The
Phoenix Research Labs, Inc., Neuropore Therapies, and UC San Diego today announced breakthrough study results from an industry-academia collaborative effort demonstrating the utility and relevance
- Sleep; the state or condition of being asleep.